Abstract: Devices, systems, and methods for ambulatory monitoring for suspected bradycardia or prolonged QT interval with simultaneous external pacing capability is provided. The device monitors the patient for a bradycardic episode and/or prolongation of the QT interval. The device provides a monitor having sensing, pacing, recording and transmission capabilities. At least two pacing electrodes are provided with adhesive backing for application to the anterior chest region with one cathode to the region of the cardiac apex and an anode to the region of the right upper sternal cardiac border. If a bradycardic or tachycardia episode is detected or prolongation of the QT is sufficient, then pacemaking energy is provided to the electrodes allowing the patient time to seek medical care without suffering the results of temporary hemodynamic instability that might otherwise be associated with dysrhythmia. The device also senses when the electrodes are no longer in contact with the patient's body.

Abstract: A device for ambulatory monitoring for suspected bradycardia or QT monitoring with simultaneous external pacing capability is provided. The device monitors the patient for a significant bradycardic episode and/or prolongation of the QT interval. The device provides a monitor having sensing, pacing, recording and transmission capabilities. At least two pacing electrodes are provided with adhesive backing for application to the anterior chest region with one cathode to the region of the cardiac apex and an anode to the region of the right upper sternal cardiac border. If a bradycardic episode is detected or prolongation of the QT is sufficient, then pacemaking energy is provided to the electrodes allowing the patient time to seek medical care without suffering the results of temporary hemodynamic instability that might otherwise be associated with dysrhythmia.

Abstract: A device for ambulatory monitoring for suspected bradycardia or QT monitoring with simultaneous external pacing capability is provided. The device monitors the patient for a significant bradycardic episode and/or prolongation of the QT interval. The device provides a monitor having sensing, pacing, recording and transmission capabilities. At least two pacing electrodes are provided with adhesive backing for application to the anterior chest region with one cathode to the region of the cardiac apex and an anode to the region of the right upper sternal cardiac border. If a bradycardic episode is detected or prolongation of the QT is sufficient, then pacemaking energy is provided to the electrodes allowing the patient time to seek medical care without suffering the results of temporary hemodynamic instability that might otherwise be associated with dysrhythmia.

Abstract: A nutritional supplement specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand. The nutritional supplement can be prepared as a powder that can be added to a food item by a human subject, a concentrate that can be mixed with water or another beverage, or incorporated into a baked good for ingestion by the human subject.

Abstract: A nutritional supplement specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand. The nutritional supplement can be prepared as a powder that can be added to a food item by a human subject, a concentrate that can be mixed with water or another beverage, or incorporated into a baked good for ingestion by the human subject.

Abstract: A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand.

Abstract: A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand.

Abstract: The invention relates to the development of a simple and inexpensive oral delivery system for customized pharmaceutical formulations for treating patients having conditions such as HIV/AIDS, cancer, and heart disease. The system includes a) a plurality of prepackaged pharmaceutical formulations containing at least two pharmacologically active ingredients in periodic (e.g., daily, twice-daily, three times a day, four times a day) dosage amounts for treating a plurality of patients having differing characteristics and particular conditions to be treated, each formulation differing in pharmacologically active ingredients and/or dosage amounts from each other, and b) a chart listing the plurality of formulations for assisting a physician in deciding which formulation to administer to a patient suffering from a particular condition based on the patient's characteristics.

Abstract: Prepackaged aqueous pharmaceutical compositions for the treatment of a condition are disclosed including at least two different pharmacologically active agents for the treatment of the condition, a buffering agent to buffer the composition, and an osmotic-adjusting agent. Additionally, a method of forming a prepackaged aqueous pharmaceutical composition for the treatment of a condition is disclosed, the method including the steps of mixing at least two different pharmacologically active agents, adding a buffering agent to the mixed at least two different pharmacologically active agents, and adding an osmotic-adjusting agent to the mixed at least two different pharmacologically active agents.

Abstract: Prepackaged aqueous pharmaceutical compositions for the treatment of cardiac conditions are disclosed including at least two different pharmacologically active agents for the treatment of a cardiac condition, a buffering agent to buffer the composition, and an osmotic-adjusting agent. Additionally, a method of forming a prepackaged aqueous pharmaceutical composition for the treatment of cardiac conditions is disclosed, the method including the steps of mixing at least two different pharmacologically active agents, adding a buffering agent to the mixed at least two different pharmacologically active agents, and adding an osmotic-adjusting agent to the mixed at least two different pharmacologically active agents.